Tonix Pharmaceuticals Announces Ribbon-Cutting Ceremony for its Infectious Disease R&D Center in Maryland

Published on :

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it will hold a ribbon-cutting ceremony at the Company’s approximately 48,000 square foot research and development center (RDC) in Frederick, Md. on October 18, 2021 at 12:00 p.m. ET. The RDC is expected to support the Company’s expanding infectious disease pipeline. This includes providing internal capacity to discover and develop vaccines and antivirals intended to support U.S. pandemic preparedness.

NOVA BioScience Center Addresses Critical Wet Lab Space Needs for Region

Published on :

Prince William County and VirginiaBio recently welcomed visitors to the new 33,000 square feet of wet lab space at the Northern Virginia BioScience Center, showcasing the county’s work toward becoming a life sciences hotspot. 

RoosterBio Names Life Science Industry Leader, Timothy M. Kelly, Ph.D., as New Chief Executive Officer

Published on :

RoosterBio Names Life Science Industry Leader, Timothy M. Kelly, Ph.D., as New Chief Executive Officer
Share Article
Dr. Kelly brings 15 years of executive-level experience to RoosterBio after having led several highly specialized life sciences manufacturing companies
“What sets Tim apart is his deep technical knowledge in cell and gene therapy technologies and the specialized manufacturing needs required by these unique therapies.” – Jon A. Rowley, PhD, founder and chief product officer, RoosterBio
FREDERICK, MD. (PRWEB) OCTOBER 05, 2021
RoosterBio, Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) bioprocess systems for cell and gene therapy product developers, today announced Timothy M. Kelly, PhD, has joined the company as Chief Executive Officer and as a member of the Board of Directors. Dr. Kelly brings 15 years of executive-level experience to RoosterBio after having led several highly specialized life sciences manufacturing companies in the U.S. and Europe.
“We are excited to welcome Tim to the RoosterBio team! Tim brings extensive leadership experience and a proven track record growing small companies into highly sustainable businesses. What sets Tim apart is his deep technical knowledge in cell and gene therapy technologies and the specialized manufacturing needs required by these unique therapies,” said…

Central Virginia Launches New ‘Cluster Accelerator’ Plan to Fast-track Development of Advanced Pharmaceutical Manufacturing

Published on :

Activation Capital, a leading entrepreneurship and ecosystem development organization, announced the launch of a cluster accelerator to catalyze the growth of advanced pharmaceutical manufacturing and R&D in Central Virginia. A coalition of private-public entities from Greater Petersburg and Greater Richmond helped form the accelerator, secured $2.5M in seed funding from GO Virginia and others, and appointed Activation Capital as the organizing entity – a first-of-its-kind initiative for the Commonwealth of Virginia.

Glyscend Therapeutics Announces Initiation of Phase 1 Clinical Trial on the Heels of Preclinical Data Presented at EASD 2021 on the Metabolic Benefits of its Oral Polymer-based Duodenal Exclusion Therapy

Published on :

Glyscend, Inc. delivered an oral presentation highlighting preclinical data from a study of its oral proprietary polymer duodenal exclusion therapy during the 57th Annual Meeting of the European Association for the Study of Diabetes on September 28, 2021. Data from earlier results were presented previously this year at the American Diabetes Association 80th Scientific Sessions. Glyscend has also been selected to present at the Obesity Society Annual Meeting in November 2021, focusing on the role of polymer-based duodenal exclusion therapy as an alternative to gastric bypass surgery for the management of obesity.

Adaptive Phage Therapeutics Awarded Additional $8 Million from U.S. Department of Defense for Clinical Advancement of Phage to Address Unmet Needs in Infectious Diseases

Published on :

Adaptive Phage Therapeutics Awarded Additional $8 Million from U.S. Department of Defense for Clinical Advancement of Phage to Address Unmet Needs in Infectious Diseases
SEPTEMBER 30, 2021
-Additional award brings APT’s total funding from the U.S. Department of Defense to $31.2 million–
–Will support APT’s PhageBankTM clinical stage programs targeting infectious diseases-
GAITHERSBURG, MD, September 30, 2021 – Adaptive Phage Therapeutics, Inc. (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the Department of Defense (DoD) has awarded the company an additional $8 million for the continued development of bacteriophage therapies (PhageBankTM) for the treatment of infectious diseases. The new funding brings the total contract awarded to APT to $31.2 million. 
“We are thrilled to have the ongoing support of the DoD in the advanced development of our PhageBank™ platform to treat drug-resistant infections across multiple indications,” said Greg Merril, CEO and co-founder of Adaptive Phage Therapeutics.  “We are thankful for the opportunity to collaborate with the U.S. military to create potentially lifesaving therapies for our nation’s service members.” 

Cartesian Therapeutics to double footprint, headcount in Gaithersburg

Published on :

Gaithersburg’s Cartesian Therapeutics Inc. is expanding its local footprint and initiating an aggressive hiring spree as the company bolsters its leadership team — and looks to get a cell therapy candidate through the clinic.
The biopharma, which already occupies about 4,500 square feet at 704 Quince Orchard Road, is taking over another 3,500 square feet adjacent to its existing space in the building, Dr. Murat Kalayoglu, president and CEO of Cartesian, told the Washington Business Journal.
The company declined to disclose the projected cost of the expansion, citing confidentiality reasons per its contract with Alexandria Real Estate Equities Inc. (NYSE: ARE), which in partnership with South Duvall — an affiliate of Rockville’s Scheer Partners — paid $6.9 million for the 80,000-square-foot office building in 2018. The building in the Gaithersburg biotech corridor is also home to a flurry of local players, including Novavax Inc. (NASDAQ: NVAX), miRecule Inc., VLP Therapeutics Inc. and others.

Maryland Urologist, Founder of Perineologic Develops Safe Approach to Prostate Cancer Biopsy

Published on :

For the past 30 years, screening for prostate-specific antigen (PSA) levels has been the gold standard for screening of prostate cancer. When high levels are found, physicians typically turn to a diagnostic biopsy using a transrectal route. However, a Maryland urologist has developed a different approach through the perineum, the strip of skin between the rectum and scrotum that is safer and more effective.

D&D Pharmatech Announces Agreement with Salubris Pharmaceuticals for Licensing and Development of DD01 in China | Business Wire

Published on :

D&D Pharmatech Announces Agreement with Salubris Pharmaceuticals for Licensing and Development of DD01 in China
D&D will receive an upfront payment of $4 million and is eligible to receive additional undisclosed milestone payments upon achievement of certain development and commercial milestones
DD01 is a GLP-1R/GCGR dual agonist in development for the treatment of obesity, NASH and diabetes
September 27, 2021 07:00 AM Eastern Daylight Time
GYEONGGI-DO, South Korea & GAITHERSBURG, Md.–(BUSINESS WIRE)–D&D Pharmatech, Inc. (D&D), a clinical-stage biotechnology company focused on development and commercialization of revolutionary medicines, today announced that Shenzhen Salubris Pharmaceuticals has acquired the rights to develop and commercialize DD01 in mainland China. DD01 is a glucagon-like peptide-1 receptor / glucagon receptor (GLP-1R/GCGR) dual agonist for the treatment of obesity, nonalcoholic steatohepatitis (NASH) and diabetes. D&D will retain all rights for the rest of the world.

Cell and Gene Therapy Sector Further Advised to Go Digital

Published on :

Luke Thorstenson, director of business development at cell and gene therapy and production technology firm Orgenesis, also says digitized manufacturing is key to production scaleup.
“A significant challenge in the production of pharma and biotech products is the automation and integration of individual manufacturing operations,” he tells GEN. “Transitioning from the current ‘analog’ labor-intensive manufacturing process to machine automated processes like those in our Orgenesis Mobile Processing Units and Labs (OMPULs) requires digitization and will allow for the same activities currently done manually by an operator to efficiently scale. We believe these steps are necessary to make life saving treatments like CAR-T available, accessible and affordable.”